Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
br Acknowledgements br Introduction Lung cancer treatment st
2019-09-18

Acknowledgements Introduction Lung cancer treatment strategies, especially molecular targeted therapy, have progressed rapidly. However, most established treatments are for adenocarcinoma of the lung, not for squamous cell carcinoma (SQCC). SQCC constitutes approximately 30% of lung cancers, w
-
The classification of CK substrates based on active enzyme
2019-09-17

The classification of CK2 substrates based on active enzyme subunit composition provides a framework for understanding the regulatory function of CK2β subunit. However, few experiments exist that functionally explore such classification [17], [18], [19], [20], [21], [22], [23]; this reflects practic
-
bcrp transporter The upregulation of PTGS and PTGS in late
2019-09-17

The upregulation of PTGS1 and PTGS2 in late gestation in mares could be linked to the high levels of estrogens produced by the fetoplacental unit. Estrogens are thought to be effective stimulators of prostaglandin production by potentially up regulating PTGS2 expression. Although a recent publicatio
-
One of the most fundamental distinctions between Ub signals
2019-09-17

One of the most fundamental distinctions between Ub signals is substrate monoubiquitination versus polyubiquitination. With the exception of the E2, UBE2W, which represents a special case because it topoisomerase inhibitor only ubiquitinates the flexible N-termini of substrates [5], [6], [20], most
-
br Conclusion The results of the current
2019-09-17

Conclusion The results of the current study show that boldness is associated with higher gene expression of drd2a, drd2b and oprd1b in zebrafish males. The results are correlational and additional experiments are needed to clarify the causal role of these receptors in zebrafish behavior. Confl
-
br The related catalytic regions of the human DNA
2019-09-17

The related catalytic regions of the human DNA ligases contain three domains, a DNA binding domain (DBD), a nucleotidyl transferase domain (NTase) and an oligonucleotide/oligosaccharide-fold binding domain (OBD) (Ellenberger and Tomkinson, 2008). Similar to DNA ligase I, the DNA ligase III polypep
-
Role of ROS signaling in regulating cell
2019-09-17

Role of ROS signaling in regulating cell death pathways has been well established. Involvement of CLIC1 in ROS production has been studied earlier. It was observed that macrophages from clic1 mice showed ~30% decrease in cellular ROS generation which effects macrophage function (Jiang et al., 2012).
-
While oxysterols were most extensively studied for its
2019-09-16

While oxysterols were most extensively studied for its potent ability to mediate feedback regulation of cholesterol biosynthesis, some early investigations showed that the enzymes involved in its syntheses were highly upregulated in macrophages and dendritic cells—an indication of possible roles in
-
br GRAIL family Gene related to anergy in lymphocytes protei
2019-09-16

GRAIL family Gene related to anergy in lymphocytes protein (GRAIL, encoded by Rnf128 gene) is a transmembrane RING-type E3 ligase involved in T cell anergy and tolerance, and also regulation of Spiperone hydrochloride mass cytoskeletal organization [52]. This E3 was initially identified in CD4+
-
We also identified Ubc as a functional
2019-09-16

We also identified Ubc13 as a functional E2 for LNX1 and determined the complex structure of LNX1–Ubc13~Ub, which depicts the first step of the ubiquitination process (Fig. 3a.). Comparing structural alignment of the RNF4 RING: Ubc13~Ub: Ube2V2 complex (PDB code 5AIU) [33] and the RNF4:Ubc13~Ub comp
-
Except for S adenosylmethionine SAM Fig sources of
2019-09-16

Except for S-adenosylmethionine (SAM, Fig. 1), sources of endogenous DNA alkylation are not well defined. Other possible sources include nitroso compounds related to the well known mutagen methylnitrosourea which are generated in vitro by nitrosation of cellular amines including amino acids, protein
-
3555 DGK is classified into the type II DGK subfamily
2019-09-16

DGKη is classified into the type II DGK subfamily [12], [13], [14], [15]. As described above, DGKη has the splice variants η1 and η2 [10]. DGKs η1 and η2 possess in common a pleckstrin homology domain at the N-terminus and a catalytic domain that is divided into two subdomains (catalytic subdomain-a
-
br Molecular modeling study Molecular
2019-09-16

Molecular modeling study Molecular modeling study was essentially needed to understand and interpret the DHFR inhibitory pattern of this new class of compounds. Computational docking is an algorithm designed to estimate two main terms. The first is to determine the suitable position and the orien
-
Introduction Cysteinyl leukotrienes CysLTs LTC LTD and
2019-09-16

Introduction Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are 5-lipoxygenase pathway metabolites of arachidonic Dynorphin A and deeply involved in bronchial asthma via activation of CysLT1 receptors [1], [2]. Specific CysLT1 receptor antagonists, including pranlukast [3], [4] and monteluk
-
br Acknowledgments br Significance The mechanisms underlying
2019-09-12
Significance The mechanisms underlying the adverse effects of Epo-stimulating agents on the reduced survival of cancer patients are not well understood.
14636 records 974/976 page Previous Next First page 上5页 971972973974975 下5页 Last page